Evidence
TAMP is supported by clinical research and on-going investigation
Pharmacokinetic and pharmacodynamic sub-study of trans-arterial vs. intravenous gemcitabine in the TIGeR-PaC phase 3 clinical trial
The phase III study: Targeted intra-arterial gemcitabine vs. continuation of IV gemcitabine plus nab-paclitaxel following induction with sequential IV gemcitabine plus nab-paclitaxel and radiotherapy for locally advanced pancreatic cancer (TIGeR-PaC) first interim analysis
Pishvaian M, López C, Zervos E, Hatoum H, Berg D, Ucar A, Boone B, Johnson T, Zureikat A, Meredith K, Chung K, Gandhi R, Nazemzadeh R, Parikh N, Novelli P, Kouri B, Laing C, Bates S, Agah R, and Goodman K. ESMO World Congress on Gastrointestinal Cancer; June 28-July 1, 2023; Barcelona, Spain.
Safety study of targeted and localized intra-arterial delivery of gemcitabine in patients with locally advanced pancreatic adenocarcinoma
Rosemurgy A, Ross SB, Vitulli PL, Malek R, Li J, and Agah R. J Pancreat Cancer. 2017;3(1):58-65.
Treatment of locally advanced pancreatic cancer using localized trans-arterial micro perfusion of gemcitabine: combined analysis of RR1 and RR2
Hatoum H, Rosemurgy A, Bastidas JA, Zervos E, Muscarella P, Edil BH, Cynamon J, Johnson DT, Thomas C, Swinson BM, Nordgren A, Vitulli P, Nutting C, Gipson M, Tsobanoudis A, and Agah R. Oncologist. 2024;29(8):690-698.
The TIGeR-PaC phase 3 clinical trial examining intra-arterial gemcitabine versus intravenous gemcitabine: Pharmacokinetic and pharmacodynamic sub-study
Nazemzadeh R, Kasi PM, Novelli PM, Zureikat AH, Pishvaian MJ, Meredith K, Hatoum H, Zervos EE, Laroia S, and Agah R. J Clin Onc. 2026;44(suppl 16):e16463.
Double-balloon catheter-mediated transarterial chemotherapy delivery in a swine model: a mechanism recruiting the vasa vasorum for localized therapies
Farsad K, Novelli PM, Laing C, Gandhi RT, Cynamon J, López CS, Stempinski ES, Strasser R, and Agah R. JVIR. 2024;35(7):1043-1048.
Trans-arterial gemcitabine micro perfusion of locally advanced pancreatic cancer enabled by coil plus glue embolization of a pancreaticoduodenal branch
Kis B, Bishop O, Salloum E, Al-Roubaie M, Kim DW, and Agah R. Radiol Case Rep. 2026;21:3012-3015.
INDICATIONS FOR USE: The RenovoCath® device is indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion.
DISCLAIMER: RenovoRx is evaluating the use of RenovoCath-enabled TAMP with gemcitabine as a combination product (known as intra-arterial gemcitabine) for the treatment of locally advanced pancreatic cancer (LAPC), including in the ongoing Phase III TIGeR-PaC trial, under a U.S. Investigational New Drug Application. Ongoing clinical studies continue to evaluate safety and clinical outcomes in patients with LAPC. For the full FDA-cleared indications for use for RenovoCath and associated contraindications, warnings, and precautions please visit: https://renovorx.com/#ifu
Take the Next Step
Your doctor will determine if TAMP is right for you and how this approach may fit within your overall treatment plan.
